Mr. Eklund joined the Childs Family Office in January 2011 with a focus on Venture Capital investments. Investment portfolio holdings include BioHaven Pharmaceuticals, Kleo Pharmaceuticals, Melinta Therapeutics, Prevention Pharmaceuticals, Stemedica Cell Technologies, Basin Holdings and J.W. Childs Asia Equities. Prior to 2011, Mr. Eklund was Managing Director/Head of Corporate Strategy and M&A at New York Life Investment Management. He has held the title of Director or Managing Director at Berkshire Capital Corporation; Furman Selz LLC and Merrill Lynch & Co. Mr. Eklund received an A.B. from Harvard College and an M.B.A. from Harvard Business School. He holds the Chartered Financial Analyst designation and is a member of the New York Society of Securities Analysts.